Predicting the Response to Immunotherapy Using Artificial Intelligence
A study published in The Lancet Oncology establishes for the first
time that artificial intelligence can process medical images to extract
biological and clinical information. By designing an algorithm and
developing it to analyse CT scan images, medical researchers at Gustave
Roussy, CentraleSupélec, Inserm, Paris-Sud University and TheraPanacea
(spin-off from CentraleSupélec specialising in artificial intelligence
in oncology-radiotherapy and precision medicine) have created a
so-called radiomic signature. This signature defines the level of
lymphocyte infiltration of a tumour and provides a predictive score for
the efficacy of immunotherapy in the patient.
In the future, physicians might thus be able to use imaging to identify biological phenomena in a tumour located in any part of the body without having to perform a biopsy.
Up to now, no marker can accurately identify those patients who will respond to anti-PD-1/PD-L1 immunotherapy in a situation where only 15 to 30% of patients do respond to such treatment. It is known that the richer the tumour environment is immunologically (presence of lymphocytes) the greater the chance that immunotherapy will be effective, so the researchers have tried to characterise this environment using imaging and correlate this with the patients’ clinical response. Such is the objective of the radiomic signature designed and validated in the study published in The Lancet Oncology.
In this retrospective study, the radiomic signature was captured, developed and validated in 500 patients with solid tumours (all sites) from four independent cohorts. It was validated genomically, histologically and clinically, making it particularly robust.
Using an approach based on machine learning, the team first taught the algorithm to use relevant information extracted from CT scans of patients participating in the MOSCATO study1, which also held tumor genome data. Thus, based solely on images, the algorithm learned to predict what the genome might have revealed about the tumour immune infiltrate, in particular with respect to the presence of cytotoxic T-lymphocytes (CD8) in the tumour, and it established a radiomic signature.
This signature was tested and validated in other cohorts including that of TCGA (The Cancer Genome Atlas) thus showing that imaging could predict a biological phenomenon, providing an estimation of the degree of immune infiltration of a tumour.
Then, to test the applicability of this signature in a real situation and correlate it to the efficacy of immunotherapy, it was evaluated using CT scans performed before the start of treatment in patients participating in 5 phase I trials of anti-PD-1/PD-L1 immunotherapy. It was found that the patients in whom immunotherapy was effective at 3 and 6 months had higher radiomic scores as did those with better overall survival.
The next clinical study will assess the signature both retrospectively and prospectively, will use larger numbers of patients and will stratify them according to cancer type in order to refine the signature.
This will also employ more sophisticated automatic learning and artificial intelligence algorithms to predict patient response to immunotherapy. To that end, the researchers are intending to integrate data from imaging, molecular biology and tissue analysis. This is the objective of the collaboration between Gustave Roussy, Inserm, Université Paris-Sud, CentraleSupélec and TheraPanacea to identify those patients who are the most likely to respond to treatment, thus improving the efficacy/cost ratio of the treatment.
// About radiomics
In radiomics, it is considered that imaging (CT, MRI, ultrasound, etc.) not only reveals the organisation and architecture of tissues but also their molecular or cellular composition. The technique involves the use of algorithms to analyse a medical image objectively in order to extract from it information which is invisible to the naked eye, such as the texture of a tumour, its micro-environment, its heterogeneity, etc. For the patient this represents a non-invasive approach that can be repeated over the course of the disease to follow its progress.
DOI : 10.1016/S1470-2045(18)30413-3
1 Results of the MOSCATO study published in Cancer Discovery : http://cancerdiscovery.aacrjournals.org/content/early/2017/03/26/2159-8290.CD-16-1396
Claire Parisel, 18.104.22.168.50.59
Priscille Riviere, 33 22.214.171.124.97
Laurence Wendling, 33 126.96.36.199.15
Catherine Martineau-Huynh, 33 188.8.131.52.65
Cécile Pérol, Tél. 33 1 184.108.40.206
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
C3.ai Named a Leader in Worldwide Industrial IoT Platforms for Energy by IDC MarketScape20.6.2019 21:16:00 CEST | Pressemelding
C3.ai, a leading enterprise AI software provider for accelerating digital transformation, today announced it has been named a leader in IIoT platforms within the energy sector according to the IDC Marketscape: Worldwide Industrial IoT Platforms in Energy 2019 Vendor Assessment (IDC #US45116919, June 2019). C3.ai delivers a software suite for rapidly developing, deploying, and operating large scale AI, predictive analytics, and IoT applications for any enterprise value chain in any industry, with a focus on industrial organizations. C3.ai software enables leading organizations to rapidly design, develop, deploy, and operate enterprise-scale AI, predictive analytics, and IoT applications. C3.ai’s growing list of customers includes 3M, Shell, Enel, New York Power Authority, the United States Air Force, Con Edison, and ENGIE. The IDC MarketScape cited customer feedback that “C3 enables customers to build models and deploy applications in less time with limited risk. These tools have enable
Hologic Enters into Exclusive Negotiations to Acquire SuperSonic Imagine, French Ultrasound Innovator20.6.2019 20:01:00 CEST | Pressemelding
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has made a binding offer to acquire (directly or through an affiliate) SuperSonic Imagine (Euronext: SSI, FR0010526814), a France-based innovator in cart-based ultrasound products, and that it has entered into an exclusive negotiation agreement with the company and its main shareholders toward that end. “Like our previous acquisitions of Faxitron and Focal, acquiring SuperSonic Imagine will strengthen our strategy to provide comprehensive screening, interventional and surgical solutions across the continuum of breast health care,” said Pete Valenti, Hologic’s Division President, Breast and Skeletal Health Solutions. “Ultrasound is becoming increasingly important in diagnosing breast cancer, and we believe SuperSonic Imagine offers superior technology that translates into better clinical outcomes for breast cancer patients, as well as for patients with liver and prostate disease.” Under the terms of
Digital Transformation Gets Bigger, Better, Bolder at LiveWorx’1920.6.2019 17:54:00 CEST | Pressemelding
A record crowd gathered in Boston last week for the annual LiveWorx® digital transformation event, where attendees explored how digital transformation is becoming a reality for an ever-increasing number of manufacturing companies around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190620005610/en/ The annual LiveWorx event brought together more than 6,400 of the industry’s greatest minds from more than 40 countries (with approximately 7,000 more live-streaming the event) with content spanning disruptive technologies including AR, IIoT, Industry 4.0 and more. LiveWorx 2020 will take place between June 8-11 in Boston's Innovation District. The event brought together more than 6,400 of the industry’s greatest minds from more than 40 countries (with approximately 7,000 more live-streaming the event) for four days of interactive workshops, facilitated industry networking, cutting-edge demos featuring the latest enter
INSERTING and REPLACING Arch Capital Group Names Seamus Fearon EVP, Credit Risk Transfer and Services, Global Mortgage Group20.6.2019 16:47:00 CEST | Pressemelding
Insert at end of first sentence of release: subject to regulatory approval. The corrected release reads: ARCH CAPITAL GROUP NAMES SEAMUS FEARON EVP, CREDIT RISK TRANSFER AND SERVICES, GLOBAL MORTGAGE GROUP Arch Capital Group Ltd. (Arch) today announced that Seamus Fearon has been promoted to Executive Vice President, Credit Risk Transfer and Services, Global Mortgage Group, subject to regulatory approval. In this role, Fearon will have responsibility for managing Arch’s credit risk transfer (CRT) business and growing its credit risk services offerings. He most recently was Chief Actuary of Arch’s Global Mortgage Group, where he oversaw its capital management framework and the development of its analytics and modeling capabilities. This newly created role highlights Arch’s focus on participating in credit risk transfer programs and supporting customers who would like to enter that growing market. “As the mortgage insurance market in the U.S. becomes even more competitive, it’s important
The “Centre Hospitalier de la Côte Basque” in France Has Started the Evaluation of the Biolog-id’s C-LOG® Solution20.6.2019 15:35:00 CEST | Pressemelding
The Centre Hospitalier de la Côte Basque (CHCB) in Bayonne has been using Biolog-id's C-LOG® solution since early April 2019. This solution secures and optimizes the circuit of chemotherapy and immunotherapy, from their preparation all the way to the administration to the patient. The C-LOG® solution has been used at the CHCB. "During the last HAS audit, a lack of traceability was revealed in the chemotherapy circuit. In order to close this gap, we decided to install the C-LOG® solution which, in addition to securing the administration to the patient's bed, makes it possible to trace the preparation circuit from the pharmacy to the reception in the nurses station," says Dr. Burtin, Pharmacist at CHCB. The solution will be tested for evaluation for 3 months before final adoption. "The RFID (Radio Frequency Identification) technology is the foundation of our solution. The tag affixed on each preparation contains the product and patient data. This information is updated in real-time and c
CSC Announces Cyber Security Findings for the Media Industry20.6.2019 15:00:00 CEST | Pressemelding
Securing a company’s digital infrastructure has become a major concern to corporations worldwide. With leading security companies and other organizations alerting corporations and the public to recent widespread, state-sponsored domain name system (DNS) hijacking, more and more brands are starting to take action. CSC has been issuing Cyber Security Reports since 2017, culling the most important information about security risks, and in particular, risks to brands that are not mitigated by a traditional firewall. The recent research conducted by CSC focuses on the media industry, revealing that 78% of global media brands use a corporate domain registrar, yet only 37% of those have a registrar lock to protect their DNS from hijacking. Recent domain hijacking, unauthorized changes, and deletion of vital domains have shown that effectively managing domain names and DNS must become a critical component for enhancing the security posture of any company with an online presence. More worrisome